Immunic, Inc. nhasi yakazivisa kutanga kwemapoka evarwere muchikamu chayo 1 chekiriniki yekuedza IMU-856, kambani yechitatu yekiriniki asset, mune varwere vane chirwere chechiliac.
IMU-856 inowanikwa nemuromo uye yakarongeka ichiita diki molecule modulator inotarisa isingazivikanwe epigenetic regulator. Zvidzidzo zvepreclinical zvinoratidza kuti IMU-856 inogona kudzoreredza basa remudumbu mudumbu uye zvakare kudzoreredza matumbo ekuvaka uku uchichengetedza immunocompetency. Kubva pane preclinical uye yekutanga data yekiriniki iripo kusvika parizvino, kambani inotenda kuti IMU-856 inogona kumiririra rinoveli uye ingangoita nzira yekupwanya yekurapa zvirwere zvemudumbu.
"Kutanga kweChikamu C chechikamu ichi 1 kliniki yekuedzwa muvarwere veceliac inoratidza chiitiko chakakosha mukuvandudzwa kwekiriniki yeIMU-856, uye tinotarisira kukwanisa kusimbisa kukwanisa kwayo kudzorera intestinal barrier function pasina kukanganisa immune system," akadaro Daniel Vitt, Ph.D., Chief Executive Officer uye Mutungamiriri weImmunic. "Nemhaka yekuti inomiririra kudikanwa kwakakosha kusingagutsikane nevanocherekedzwa vakanyatsocherechedzwa mamaki echiitiko chechirwere, isu tinotenda kuti chirwere chechiliac ndiyo yakanaka yekutanga kiriniki chiratidzo chekupa humbowo-hwe-pfungwa yeIMU-856's acute uye isingaperi kukanganisa. IMU-856's mechanism inogona kupa nzira itsva yekurapa nhamba yakawanda yezvirwere zvakakomba uye zvakapararira, uye tinotenda kuti inogona kupa rubatsiro rwekliniki pasina migumisiro yakakomba inobatanidza nemishonga yakawanda ye autoimmune. Zvakare, isu tinotarisira kupa data rakazara rekuchengetedza rakaiswa kubva kune imwechete uye yakawanda inokwira dosi zvikamu zveichi chirikuitika chikamu 1 chekiriniki yekuedza muzvidzidzo zvevanhu vane hutano, parizvino inotarisirwa kuwanikwa muchikamu chechitatu chegore rino. "
"Chirwere cheCeliac chirwere chehupenyu hwese uye chakakomba autoimmune chemukati madiki ane pathophysiology inokonzerwa nekukuvadzwa-kunokonzerwa neguten kumadziro emukati. Pasinei nekuomerera kune kudya kusina gluten, varwere vakawanda vanoona chirwere chinoramba chichienderera mberi chinogona kutungamirira kumararamiro asingagumi, kurwadziwa kwepamuviri, malabsorption yezvokudya uye kunyange kuwedzera kwengozi yeanemia, osteoporosis nedzimwe kenza," akadaro Andreas Muehler, MD, Chief Medical Officer. yeImmunic. "Pane kudiwa kukuru kwekupindira kwekurapa kunoshanda kune varwere vane chirwere chechiliac, sezvo nzira chete yekurapa nhasi ndeyekudya kwakasimba, kwehupenyu hwese-gluten-isina kudya, inorema, kazhinji inorambidza magariro, uye inogara ichitadza kumisa chirwere. . Tichifunga nezve IMU-856 inogona kudzoreredza mutumbu inovharira basa uye kugadzirwa kwemukati, isu tinotenda kuti komisheni iyi ine vimbiso mukuvandudza hutano hwemudumbu hwevarwere uye kugona kugaya uye kutora zvinovaka muviri, nekudaro kuderedza mhedzisiro yenguva refu uye kuvandudza kunaka kwavo. hupenyu, zviratidzo zvechirwere uye zvinogona kuitika mune ramangwana. "
Zvikamu A uye B zvechikamu chinoenderera mberi 1 kliniki yekuedza iri kuongorora imwe chete uye yakawanda inokwira doses yeIMU-856 muzvidzidzo zvevanhu vane hutano. Ikozvino yatangwa Chikamu C chakarongeka semazuva makumi maviri nemasere, maviri-mapofu, anodzorwa ne placebo akagadzirirwa kuongorora kuchengetedzwa uye kushivirira kweIMU-28 kune varwere vane chirwere chechiliac panguva dzekudya kweguten uye gluten dambudziko. Vanosvika varwere makumi mana nevaviri vakarongerwa kunyoreswa mumapoka maviri akateedzana neIMU-856 inopihwa kamwe-zuva nezuva kwemazuva makumi maviri nemasere. Zvinangwa zvechipiri zvinosanganisira pharmacokinetics uye zviratidzo zvechirwere, kusanganisira izvo zvinoongorora gastrointestinal kuvaka uye kuzvimba. Angangoita gumi masaiti muAustralia neNew Zealand anotarisirwa kutora chikamu muChikamu C.
Iyo kambani zvakare inodzokorora kutungamira kwayo kwekutanga kuti chikamu chechipiri chepamusoro-mutsara data ye vidofludimus calcium (IMU 2) muulcerative colitis inotarisirwa kuwanikwa muna Chikumi 838 uye kuti yekutanga kiriniki inoshanda data yeChikamu C chikamu chechirikuenderera chikamu 2022 chekiriniki. kuyedzwa kweIMU-1 mu psoriasis inotarisirwa muhafu yechipiri ya935.
ZVOKUBVA MUNYAYA INO:
- Iyo kambani zvakare inodzokorora kutungamira kwayo kwekutanga kuti chikamu chechipiri chepamusoro-mutsara data ye vidofludimus calcium (IMU 2) muulcerative colitis inotarisirwa kuwanikwa muna Chikumi 838 uye kuti yekutanga kiriniki inoshanda data yeChikamu C chikamu chechirikuenderera chikamu 2022 chekiriniki. kuyedzwa kweIMU-1 mu psoriasis inotarisirwa muhafu yechipiri ya935.
- “Start of Part C of this phase 1 clinical trial in celiac disease patients marks an important milestone in the clinical development of IMU-856, and we hope to be able to confirm its ability to restore intestinal barrier function without affecting the immune system,”.
- The now initiated Part C is structured as a 28-day, double-blind, placebo-controlled trial designed to assess the safety and tolerability of IMU-856 in patients with celiac disease during periods of gluten-free diet and gluten challenge.
